Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology has initiated enrollment of subjects in the bioequivalency clinical trial of MetControl, the company's proprietary metformin medicinal chewing gum product.
Subscribe to our email newsletter
A study is currently being conducted in the US wherein the site is actively screening and enrolling subjects. The protocol for the study is an open-label, two-treatment, two-period, randomized, crossover study comparing MetControl and immediate release metformin tablets in healthy volunteers.
The study results will allow the company to proceed with additional R&D initiatives and consider regulatory agency registration applications.
Metformin is a generic drug used to regulate blood glucose levels by reducing liver glucose production and improving the insulin sensitivity of cells. Metformin is the backbone of almost all treatments for Type 2 diabetes mellitus.
Rose Perri, COO of Generex, said: “We are excited about the commencement of this study on our proprietary metformin gum product. We have high expectations for this product to enhance the company’s already growing diabetes product pipeline.”